Widarlane Ângela da Silva Alves

Ms. Widarlane Ângela da Silva Alves

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MBMariana de M. Barbosa
Mariana de M. Barbosa
LLLidiane Lima
Lidiane Lima
WAWidarlane Ângela da Silva Alves
Widarlane Ângela da Silva Alves
ELEucilene K. B. de Lima
Eucilene K. B. de Lima
Luzia Abilio SilvaLuzia Abilio Silva
Luzia Abilio Silva
ELEduardo Carvalho Lira
Eduardo Carvalho Lira
Polyoxovanadates (POV) are a subgroup of polyoxometalates (POM), which are nanosized clusters with reported biological activities. This manuscript describes the first toxicity evaluation of a mixed-valence polyoxovanadate, pentadecavanadate, (Me4N)6[V15O36Cl], abbreviated as V15. Cytotoxicity experiments using peripheral blood mononuclear cells (PBMC), larvae of Artemia salina Leach, and in vivo oral acute and repeated 28-day doses in mice was carried out. The LC50 values in PBMC cells and A. salina were 17.5 ± 5.8 μmol L−1, and 17.9 µg L−1, respectively, which indicates high cytotoxic activity. The toxicity in mice was not observed upon acute exposure in a single dose, however, the V15 repeated 28-day oral administration demonstrated high toxicity using 25 mg/kg, 50 mg/kg and, 300 mg/kg doses. The biochemical and hematological analyses during the 28-day administration of V15 showed significant alteration of the metabolic parameters related to the kidney and liver, suggesting moderate toxicity. The V15 toxicity was attributed to the oxidative stress and lipid peroxidation, once thiobarbituric acid (TBAR) levels significantly increased in both males and females treated with high doses of the POV and also in males treated with a lower dose of the POV. This is the first study reporting a treatment-related mortality in animals acutely administrated with a mixed-valence POV, contrasting with the well-known, less toxic decavanadate. These results document the toxicity of this mixed-valence POV, which may not be suitable for biomedical applications.

10 January 2026 in Injury
Verified
Journal Article
Closed access
BBBianca Rocha da Silva Barreto
Bianca Rocha da Silva Barreto
ELEduardo Carvalho Lira
Eduardo Carvalho Lira
SJSeverino A. Junior
Severino A. Junior
Luzia Abilio SilvaLuzia Abilio Silva
Luzia Abilio Silva
YSYuri José de Albuquerque Silva
Yuri José de Albuquerque Silva
JVJeymesson Vieira
Jeymesson Vieira